Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ANXA2<sup>+</sup>/TNR<sup>-</sup> glioblastoma subpopulation drives tumor progression through via Src-STAT3 axis and neutrophil remodeling.

International immunopharmacology·2026
Same author

Propofol attenuates pain hypersensitivity and neuroinflammation in chronic constriction injury rats by regulating miR-1249-3p/VEGFA axis.

The Korean journal of pain·2026
Same author

Genomic Analysis of Ocular Pseudomonas aeruginosa Isolates: Insights From a Predominantly Asian, Multi-Regional Dataset.

Investigative ophthalmology & visual science·2026
Same author

Global epidemiological survey and genomic analysis of multiple carbapenemases-producing Citrobacter freundii.

Journal of global antimicrobial resistance·2026
Same author

Causal effects of psoriasis on breast cancer risk: The contribution of emotional distress explored by Mendelian randomization.

Medicine·2026
Same author

Genome and transcriptome analyses reveal parallel altitude adaptation in Chenopodium.

Genome biology·2026
Same journal

Successful Use of Electroconvulsive Therapy in Treatment-Resistant Catatonia With Comorbid Parkinson Disease and Neuroborreliosis: A Case Report.

The journal of ECT·2026
Same journal

Electroconvulsive Therapy in Movement Disorders: A Systematic Review.

The journal of ECT·2026
Same journal

Presyncope During Repetitive Transcranial Magnetic Stimulation With Treatment Continuation.

The journal of ECT·2026
Same journal

Comparison of Electroconvulsive Therapy Seizure Outcomes When Using Methohexital Versus Propofol: A Brief Retrospective Report.

The journal of ECT·2026
Same journal

Changes in the Use of Repetitive Transcranial Magnetic Stimulation Therapy Between 2016 and 2022 in Northern Finland.

The journal of ECT·2026
Same journal

Evaluation of Cardiac Adverse Effects After Transition From Bitemporal to Bifrontal ECT.

The journal of ECT·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Topiramate for post-electroconvulsive therapy headaches.

Lu Ye1, Surya Kumar Karlapati, Steven Lippmann

  • 1Methodist Medical Center of Illinois, Peoria, IL 61602, USA. lye@mmci.org

The Journal of ECT
|August 23, 2013
PubMed
Summary
This summary is machine-generated.

Headache is a common side effect of electroconvulsive therapy (ECT). Topiramate effectively treated persistent ECT headaches unresponsive to standard pain medications.

More Related Videos

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury
07:07

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury

Published on: February 10, 2020

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Related Experiment Videos

Last Updated: May 8, 2026

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury
07:07

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury

Published on: February 10, 2020

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Electroconvulsive therapy (ECT) is a medical treatment for severe mental health conditions.
  • Headache is a frequent adverse effect following ECT procedures.

Observation:

  • Standard analgesics like acetaminophen, NSAIDs, muscle relaxants, and narcotics offer limited relief for post-ECT headaches.
  • A patient experienced a severe headache after ECT that did not improve with conventional pain management.

Findings:

  • Topiramate demonstrated efficacy in resolving a persistent headache after electroconvulsive therapy.
  • This suggests topiramate may be a viable treatment option for refractory post-ECT headaches.

Implications:

  • Topiramate could offer a novel therapeutic strategy for managing challenging post-ECT headaches.
  • Further research is warranted to confirm topiramate's effectiveness and safety in this patient population.